• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

head and neck squamous cell carcinoma (HNSCC) - Articles and news items

FDA Merck approval head and neck cancer

FDA approves Merck’s head and neck cancer drug

Industry news / 8 August 2016 / Merck

Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon verification and description of clinical benefit in the confirmatory trials…

keytruda

Merck releases new data for Keytruda at ASCO

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells…

head-and-neck-cancer

FDA accepts sBLA for Keytruda in head and neck cancer

Industry news / 13 April 2016 / Victoria White, Digital Content Producer

The sBLA is for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy…

il-12

First patient enrolled in Phase II trial of ImmunoPulse IL-12

Industry news / 17 June 2015 / Victoria White

OncoSec has enrolled the first patient into a Phase II clinical trial of ImmunoPulse IL-12 in patients with squamous cell carcinoma of the head and neck…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +